Is another ODT excipient necessary? - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Is another ODT excipient necessary?

Pharmaceutical Technology Europe
Volume 21, Issue 9

Yes, we do need a new ODT excipient

In answer to the earlier question "Is there a need for another excipient system for direct compression and fast dissolution?", we believe that the answer is "yes"; there is certainly a use for a new ODT formulation. The combination of two components in Parteck ODT — one binder and a superdisintegrant — shows valuable characteristics for direct compression. Through its large surface area, the formulator can achieve high tablet strength at low friability while still achieving fast disintegration and a pleasant mouth feel. Tablets produced with Parteck ODT exhibit rapid disintegration within the oral cavity, as well as fast release of the active. We believe that this excipient system speeds up the regulatory registration process and is compatible with most actives, making it a good, economical option.

H. Leonhard Ohrem is Technical Manager at Merck KGaA (Germany).

Roberto Ognibene is Technical Support, Merck KGaA (Germany).


1. P. van Arnum, Pharm. Technol., 31(10), 66–76 (2007).

2. FDA Guidance for Industry — Orally Disintegrating Tablets, December 2008.

3. European Pharmacopoeia 6.0, Orodospersible Tablets, July 2007.

4. R. Bohnacker et al., Pharm. Ind., 67(3), 327–335 (2005).

5. W. Camarco, D. Ray and A. Druffner, Pharm. Technol., 30(10), 27–37 (2006).

6. USP 24-NF 19.

7. M. Bertoni, F. Ferrari and C. Caramella, Pharm. Technol. Eur., 17(11), 17–24 (1995).

8. M.S. Gordon, B. Chatterjee and Z.T. Chowhan, J. Pharm. Sci., 79(1), 43–47 (1990).

9. C. Ferrero et al., Int. J. Pharm., 147, 11–21 (1997).


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology Europe,
Click here